Vaccine

Why is PrIMAVeRa needed?

Antimicrobial resistance (AMR) is estimated to be responsible for the loss of 700,000 lives annually. This figure is projected to reach 10 million by the year 2050, according to the United Nations Interagency Coordination Group on Antimicrobial Resistance.  It is crucial to be able to rank potential interventions against AMR according to their cost-effectiveness in order to make good use of limited resources. However, there are currently no comprehensive models to inform the decisions of policymakers as to on which measures have the potential to be the most beneficial.  

 

PrIMAVeRa aims to develop and refine models to quantitatively predict the economic and health outcomes of various potential courses of action, helping to reveal the optimal path forward for those steering the fight against AMR.